The stock of Advaxis, Inc. (NASDAQ:ADXS) is a huge mover today! About 341,793 shares traded hands. Advaxis, Inc. (NASDAQ:ADXS) has risen 3.83% since April 14, 2016 and is uptrending. It has underperformed by 0.86% the S&P500.
The move comes after 6 months positive chart setup for the $422.40M company. It was reported on Nov, 16 by Barchart.com. We have $27.43 PT which if reached, will make NASDAQ:ADXS worth $692.74M more.
Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage
Out of 2 analysts covering Advaxis (NASDAQ:ADXS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Advaxis has been the topic of 2 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The rating was initiated by Barclays Capital with “Overweight” on Tuesday, September 22. The stock has “Buy” rating given by Guggenheim on Friday, September 11.
According to Zacks Investment Research, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P.”
Insitutional Activity: The institutional sentiment increased to 2.38 in Q2 2016. Its up 1.20, from 1.18 in 2016Q1. The ratio is positive, as 7 funds sold all Advaxis, Inc. shares owned while 14 reduced positions. 11 funds bought stakes while 39 increased positions. They now own 21.74 million shares or 0.17% less from 21.77 million shares in 2016Q1.
Allianz Asset Ag last reported 0% of its portfolio in the stock. Teacher Retirement Systems Of Texas last reported 4,654 shares in the company. The New York-based D E Shaw And Company Inc has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Franklin Street Nc, a North Carolina-based fund reported 136,350 shares. Ladenburg Thalmann Financial Ser Inc has 5,000 shares for 0% of their US portfolio. Cormorant Asset Mngmt holds 809,804 shares or 0.93% of its portfolio. Morgan Stanley has invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Da Davidson & Co last reported 75,000 shares in the company. Wells Fargo Co Mn last reported 25,589 shares in the company. Cim Investment Mangement holds 10,153 shares or 0.03% of its portfolio. Broadfin Limited Liability, a New York-based fund reported 1.69M shares. Orbimed Advsr Ltd Liability Corporation accumulated 0.04% or 445,400 shares. Vident Advisory Limited Liability last reported 79,843 shares in the company. Northern Cap Mgmt Lc has invested 0.06% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). The Delaware-based Blackrock Advsr Ltd Limited Liability Company has invested 0% in Advaxis, Inc. (NASDAQ:ADXS).
Insider Transactions: Since August 8, 2016, the stock had 0 insider buys, and 5 insider sales for $1.11 million net activity. The insider SIDRANSKY DAVID sold $342,348. O’Connor Daniel sold $68,557 worth of Advaxis, Inc. (NASDAQ:ADXS) on Monday, October 31. PETIT ROBERT also sold $23,271 worth of Advaxis, Inc. (NASDAQ:ADXS) on Monday, October 31. $157,703 worth of Advaxis, Inc. (NASDAQ:ADXS) was sold by Mayes – Gregory T. on Tuesday, October 25. BERMAN RICHARD J sold $520,755 worth of Advaxis, Inc. (NASDAQ:ADXS) on Monday, August 8.
ADXS Company Profile
Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants. The Company’s immunotherapy candidates include Axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.